All In Biotech

Drug Trial Radar · NCT02185456

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

Last checked: Nov 19, 2026Latest source record: Nov 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 2014

Primary completion

Jan 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Wayne State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jul 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Bacterial vaginosis (BV) is the commonest form of vaginitis worldwide, affecting millions of women. Unfortunately, recurrence rates of symptomatic BV remain extremely high, 30% at three months and 70-80% within a year. Given the paucity of information and data regarding pathogenesis of BV, the etiopathogenesis of recurrent bacterial vaginosis remains unknown. Accordingly, reliable, proven treatment regimens for Recurrent Bacterial Vaginosis (RBV) are not available. In 2013, the investigators published two manuscripts documenting a new qPCR based approach to BV diagnosis and potentially prognosis. The method (LbRC) measures the content of lactobacilli in vaginal samples, relative to total bacterial load. The first goal of this study are to validate that this metric is a reliable diagnostic of BV, by determining sensitivities and specificities relative to Nugent scores and Amsel criteria of healthy women and BV patients. A high LbRC score (3-4) corresponds to a healthy state. The second goal is to determine whether empirically determined "low" LbRC scores (1-2) in BV patients after treatment are indicators of recurrence, and whether preemptive action, based on this score, with more intensive treatment, delays or eliminates recurrence in these patients.

Conditions

  • Bacterial Vaginosis

Interventions

  • 750 mg metronidazole/ 200 mg miconazole vaginal suppositoryDrug

    The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.

  • Standard of careDrug

    oral metronidazole 500 mg twice a day for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnosis of bacterial vaginosisTime frame: Monthly for up to nine months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WSU Tolan Park Medical Building 3901 Chrysler Service Drive, Suite 4A

    Detroit, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.